DURECT to Participate in Upcoming Healthcare Conferences
CUPERTINO, Calif., Aug. 21, 2012 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at two upcoming healthcare conferences.
- Matt Hogan, Chief Financial Officer, will present at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5 at 3:15 p.m. Eastern Time. The conference is being held at the Four Seasons Hotel in Boston. A live audio webcast of the presentation will be available by accessing http://www.veracast.com/webcasts/stifel/healthcare2012/36113426.cfm.
- James E. Brown, President and CEO, will also present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10 at 3:40 p.m. Eastern Time. The conference is being held at the Waldorf Astoria in New York. A live audio webcast of the presentation will be available by accessing http://www.wsw.com/webcast/rrshq22/drrx.
A live audio webcast of these presentations will also be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is a specialty pharmaceuticalcompany developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
NOTE: POSIDUR™, SABER™, ORADUR®, TRANSDUR®, ELADUR™ and DURIN® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
SOURCE DURECT Corporation